Oat-grape probiotic beverage enriched with jambolan extract improves glycemic markers and pancreatic morphology in a rat model of type 2 diabetes.
文献摘要
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease accounting for approximately 90% of all diabetes cases worldwide, highlighting the need for effective prevention and management strategies. This study aimed to evaluate the effects of an oat-grape probiotic beverage enriched with 3% jambolan (Syzygium cumini) extract (PBA3) containing Lactobacillus acidophilus LA14 in Wistar rats with T2DM. Rats were randomized into four groups: healthy control (H), healthy treated with PBA3 (HB), diabetic (D), and diabetic treated with PBA3 (DB). Healthy groups received a standard diet, whereas diabetic groups received a high-sugar diet and streptozotocin (50 mg/kg). PBA3 was administered daily by oral gavage (10 mL/kg) for 4 weeks. Metabolic, inflammatory, and histopathological parameters were evaluated, including glucose homeostasis, insulin sensitivity, glycated hemoglobin (HbA1c), pancreatic histopathology, pancreatic and colonic tumor necrosis factor (TNF) immunoreactivity, and short-chain fatty acids (SCFA) in intestinal contents and feces. Compared with the untreated diabetic group (D), PBA3 improved glucose homeostasis and insulin sensitivity, as demonstrated by significant reductions in fasting glucose, glycated hemoglobin, and HOMA-IR, together with improved insulin tolerance. Treatment also increased SCFA, reuced pancreatic TNF immunoreactivity, and preserved pancreatic islet morphology. These findings provide exploratory preclinical evidence that PBA3 is associated with improved glycemic markers, insulin sensitivity, SCFA, and attenuation of pancreatic inflammatory and structural alterations in this experimental model, supporting further mechanistic and translational investigation of its potential in T2DM management.